Search Results | Blood | American Society of Hematology

1-20 of 519

2 3 4 5

Sort by

Sort Order Select

Journal Articles

Natural History Study of Idiopathic Multicentric Castleman Disease Identifies Effective Treatments for a Large Proportion of Patients but Treatment-Refractory Patients Remain

Blood (2019) 134 (Supplement_1): 1540.

DOI: https://doi.org/10.1182/blood-2019-131367

Published: 2019

Journal Articles

Superior Outcome in Elderly AML Patients Receiving Adjuvant Serotonin-Reuptake-Inhibitors during Induction

Rafee Talukder, MD, Martha P. Mims, MD PhD, Gustavo A. Rivero, MD

Blood (2019) 134 (Supplement_1): 1438.

DOI: https://doi.org/10.1182/blood-2019-131581

Published: 2019

Journal Articles

Primary Bone Non-Hodgkin's Lymphoma: A Specific Clinical Entity with Aggressive Clinical Course and High Cure Rate - Retrospective Analysis of 102 Patients from Greece

Argiris Symeonidis, MD PhD, Sotirios Papageorgiou, MD PhD, Antonis Patrinos, MD, Maria Melachrinou, MD PhD, Alexandra Kourakli, MD PhD, Vassiliki Pappa, MD, Maria K. Angelopoulou, MD, Anastasia Sioni, Nikolaos Kanellias, MD, Sofia Chatzileontiadou, MD, Eleftheria Hatzimichael, Panagiotis Zikos, Anastasia Pouli, MD PhD, Maria Papaioannou, Evangelos Terpos, MD PhD, Gerasimos Pangalis, MD, Theodoros P. Vassilakopoulos, MD PhD

Blood (2019) 134 (Supplement_1): 5340.

DOI: https://doi.org/10.1182/blood-2019-130219

Published: 2019

Journal Articles

Carfilzomib Based Regimens for Treatment of Newly Diagnosed Multiple Myeloma: A Systematic Review

Maimoona Khan, MBBS, Asma Waheed, MBBS, Rida Ul Jannat, MBBS, Arafat Ali Ali Farooqui, MD, Muhammad Saad Farooqi, MD, Ali Younas Khan, MD, Madeeha Shafqat, Muhaddis Ejaz Ahmad, MD, Muhammad Abdullah Yousaf, MBBS, MD, Tariq Iqtidar Sadiq Syed, MD, Syed Maaz Abdullah, MBBS, Sravanthi Kotapati, MBBS, Irbaz Riaz, MDMMSc, Faiz Anwer, MD

Blood (2019) 134 (Supplement_1): 5588.

DOI: https://doi.org/10.1182/blood-2019-128833

Published: 2019

Journal Articles

A Single Institution Experience of Bortezomib for Gvhd in a Pediatric HSCT Population

Devangi Shah, Jennifer Reichbach Douglas, DNP, APRN, CPHON, Jumana Ashy, Gregory Suhrheinrich, Edward Dela Ziga, MD, Asha B. Pillai, MD, Julio C Barredo, MD, Warren Alperstein, MD

Blood (2019) 134 (Supplement_1): 5680.

DOI: https://doi.org/10.1182/blood-2019-125884

Published: 2019

Journal Articles

Profile of Long-Term Survivors in Multiple Myeloma

Blood (2019) 134 (Supplement_1): 5522.

DOI: https://doi.org/10.1182/blood-2019-127519

Published: 2019

Journal Articles

Three Drug Regimens for Newly Diagnosed Multiple Myeloma Transplant-Ineligible Elderly Patients - a Systematic Review

Abdul Aziz Siddiqui, MD, Kazi Najamus-saqib Khan, Arafat Ali Farooqui, MD, Muhammad Saad Farooqi, MD, Muhammad Junaid Tariq, MD, Faiz Anwer, MD

Blood (2019) 134 (Supplement_1): 5574.

DOI: https://doi.org/10.1182/blood-2019-132095

Published: 2019

Journal Articles

Incidence and Outcomes of Extramedullary Myeloma in a South Australian Hospital

Angelina Yong, BSc,BMBS, FRACP, FRCPA

Blood (2019) 134 (Supplement_1): 5504.

DOI: https://doi.org/10.1182/blood-2019-129754

Published: 2019

Journal Articles

Dissecting Heterogeneity of Tumor Cells and Their Microenvironment in Refractory Multiple Myeloma

Stephan M Tirier, PhD, Jan-Philipp Mallm, PhD, Nicola Casiraghi, PhD, Hana Susak, PhD, Nicola Giesen, MD, Alexandra M Poos, PhD, Katharina Bauer, Anja Baumann, Lukas John, MD, Jing Xu, PhD, Lara Klett, MSc, Carsten Müller-Tidow, MD, Benedikt Brors, PhD, Hartmut Goldschmidt, MD, Niels Weinhold, PhD, Oliver Stegle, PhD, Karsten Rippe, PhD, Marc S. Raab, MD

Blood (2019) 134 (Supplement_1): 571.

DOI: https://doi.org/10.1182/blood-2019-128625

Published: 2019

Journal Articles

Preclinical Evaluation for Engraftment of Gene-Edited CD34+ Cells with a Sickle Cell Disease Mutation in a Rhesus Transplantation Model

Naoya Uchida, MD, Linhong Li, PhD, Tina Nassehi, Morgan Yapundich, Jackson Gamer, Claire Drysdale, Juan J. Haro-Mora, PhD, Selami Demirci, PhD, Aylin Bonifacino, MS, Allen Krouse, Nathaniel S. Linde, Cornell Allen, MS, Suk See De Ravin, MD, PhD, Robert E. Donahue, VMD, Harry L. Malech, MD, Madhusudan Peshwa, PhD, John F. Tisdale, MD

Blood (2019) 134 (Supplement_1): 609.

DOI: https://doi.org/10.1182/blood-2019-122727

Published: 2019

Journal Articles

Efficacy and Safety of Azacitidine (AZA) in Combination with the Anti-PD-L1 Durvalumab (durva) for the Front-Line Treatment of Older Patients (pts) with Acute Myeloid Leukemia (AML) Who Are Unfit for Intensive Chemotherapy (IC) and Pts with Higher-Risk Myelodysplastic Syndromes (HR-MDS): Results from a Large, International, Randomized Phase 2 Study

Amer M. Zeidan, MBBS, MHS, James Cavenagh, Maria Teresa Voso, David Taussig, Mar Tormo, Isaac Boss, Wilbert B. Copeland, Vanessa E. Gray, Alessandro Previtali, Tim O'Connor, Shelonitda Rose, CL Beach, Lewis R. Silverman

Blood (2019) 134 (Supplement_1): 829.

DOI: https://doi.org/10.1182/blood-2019-122896

Published: 2019

Journal Articles

Breaking the Glass Ceiling of Age in Transplant in Multiple Myeloma

Pashna N. Munshi, MD, Parameswaran Hari, MBBS, MD, David H. Vesole, MD PhD, Artur Jurczyszyn, MD, Jan Zaucha, MD PhD, Omar Davila, Shaji K. Kumar, MD, Nina D. Shah, MD, Muzaffar H. Qazilbash, MD, Anita D'Souza, MDMS

Blood (2019) 134 (Supplement_1): 782.

DOI: https://doi.org/10.1182/blood-2019-124804

Published: 2019

Journal Articles

Biallelic Inactivation of Multiple Tumor Suppressors Is Associated with Early Relapse after Stem Cell Transplant in Newly Diagnosed Myeloma

Niels Weinhold, PhD, Jing Xu, PhD, Martina Fröhlich, PhD, Alexandra M Poos, PhD, Lukas John, MD, Carsten Müller-Tidow, MD, Sandra Sauer, MD, Stefanie Huhn, PhD, Dirk Hose, MD, Anja Seckinger, Kari Hemminki, MD PhD, Benedikt Brors, PhD, Hartmut Goldschmidt, MD, Nicola Giesen, MD, Marc S Raab, MD PhD

Blood (2019) 134 (Supplement_1): 1783.

DOI: https://doi.org/10.1182/blood-2019-131195

Published: 2019

Journal Articles

Dynamics of Activated CD8+ T-cells and Decreased Osteoclasts in the Tumor Microenvironment are Associated with Clinical Efficacy of Anti-PD-L1 and Anti-CD38 Combination Treatment in Relapsed or Refractory Multiple Myeloma

Aparna Raval, PhD, Hearn Jay Cho, MD PhD, Cherie Green, BS, Elisabeth Wassner Fritsch, PharmD, Connie Ma, MS, Naomi Chang, MSc, Mark Yan, PhD, Mark Kockx, MD PhD, Shine Shen, MS, Ling-Yuh Huw, PhD, Emily Balestiere, BA, Marina Lipkind, BS, Huang Huang, MSc, Michelle Byrtek, PhD, Dawn Colburn, PharmD, BCOP, Sandy W. Wong, Jeffrey M. Venstrom, MD PhD, Joanne I Adamkewicz, PhD

Blood (2019) 134 (Supplement_1): 1907.

DOI: https://doi.org/10.1182/blood-2019-123652

Published: 2019

Journal Articles

First-in-Human Assessment of Feasibility and Safety of Multiplexed Genetic Engineering of Autologous T Cells Expressing NY-ESO -1 TCR and CRISPR/Cas9 Gene Edited to Eliminate Endogenous TCR and PD-1 (NYCE T cells) in Advanced Multiple Myeloma (MM) and Sarcoma

Blood (2019) 134 (Supplement_1): 49.

DOI: https://doi.org/10.1182/blood-2019-122374

Published: 2019

Journal Articles

Reduced Relapse Risk in Children with Acute Myeloid Leukemia (AML) Who Experience Septic Shock (SS)

Alix E. Seif, MD, Yimei Li, PhD, Viviane C. Cahen, Yuan-Shung V. Huang, MS, Matt Hall, PhD, E. Anders Kolb, MD, Brian T. Fisher, DO, MSCE, Richard Aplenc, MD PhD, Kelly D Getz

Blood (2019) 134 (Supplement_1): 3496.

DOI: https://doi.org/10.1182/blood-2019-122887

Published: 2019

Journal Articles

Real-World Treatment Patterns and Transfusion Burden Among US Patients with Newly Diagnosed Myelodysplastic Syndromes (MDS)

Sudipto Mukherjee, MD PhD MPH, S. Lane Slabaugh, Ronda Copher, Jonathan Johnson, Paul Buzinec, Elizabeth S. Mearns

Blood (2019) 134 (Supplement_1): 3499.

DOI: https://doi.org/10.1182/blood-2019-123425

Published: 2019

Journal Articles

Rituximab for Preventing Delayed Hemolytic Transfusion Reaction (DHTR) in Sickle CELL Adult Patients: Outcome of Transfusion and SIDE Effects in 58 CASES

Fabian Zanchetta-Balint, France Pirenne, MD PhD, Marc Michel, Armand Mekontso-Dessap, MD PhD, Matthieu Mahevas, MD, Constance Guillaud, MD, Keyvan Razazi, MD, Elena Foïs, MD, Frédéric Galactéros, MD PhD, Pablo Bartolucci, MD PhD, Anoosha Habibi

Blood (2019) 134 (Supplement_1): 3687.

DOI: https://doi.org/10.1182/blood-2019-130874

Published: 2019

Journal Articles

Serum Free Light Chain Assay As an Additional Tool for Defining Response and Progressive Disease in Immunoglobulin Secretory Multiple Myeloma

Paola Tacchetti, Serena Rocchi, Luca Dozza, Elena Zamagni, MD, Isola Caratozzolo, MD, Ilaria Rizzello, Alessio Fusco, MD, Gabriella De Cicco, MD, Lucia Pantani, MD, Katia Mancuso, Carolina Terragna, Nicoletta Testoni, Pier Luigi Luigi Zinzani, MD, Michele Cavo

Blood (2019) 134 (Supplement_1): 1796.

DOI: https://doi.org/10.1182/blood-2019-128715

Published: 2019

Journal Articles

The Transcriptome of Immunomodulator-Resistant Multiple Myeloma

Moritz Binder, MDMPH, S. Vincent Rajkumar, MD, Martha Q. Lacy, MD, Jessica L. Haug, Angela Dispenzieri, MD, Kimberly J. Henderson, Teresa K. Kimlinger, Shaji K. Kumar, MD

Blood (2019) 134 (Supplement_1): 1772.

DOI: https://doi.org/10.1182/blood-2019-123407

Published: 2019

2 3 4 5

NARROW

Natural History Study of Idiopathic Multicentric Castleman Disease Identifies Effective Treatments for a Large Proportion of Patients but Treatment-Refractory Patients Remain

Superior Outcome in Elderly AML Patients Receiving Adjuvant Serotonin-Reuptake-Inhibitors during Induction

Primary Bone Non-Hodgkin's Lymphoma: A Specific Clinical Entity with Aggressive Clinical Course and High Cure Rate - Retrospective Analysis of 102 Patients from Greece

Carfilzomib Based Regimens for Treatment of Newly Diagnosed Multiple Myeloma: A Systematic Review

A Single Institution Experience of Bortezomib for Gvhd in a Pediatric HSCT Population

Profile of Long-Term Survivors in Multiple Myeloma

Three Drug Regimens for Newly Diagnosed Multiple Myeloma Transplant-Ineligible Elderly Patients - a Systematic Review

Incidence and Outcomes of Extramedullary Myeloma in a South Australian Hospital

Dissecting Heterogeneity of Tumor Cells and Their Microenvironment in Refractory Multiple Myeloma

Preclinical Evaluation for Engraftment of Gene-Edited CD34+ Cells with a Sickle Cell Disease Mutation in a Rhesus Transplantation Model

Breaking the Glass Ceiling of Age in Transplant in Multiple Myeloma

Biallelic Inactivation of Multiple Tumor Suppressors Is Associated with Early Relapse after Stem Cell Transplant in Newly Diagnosed Myeloma

Dynamics of Activated CD8+ T-cells and Decreased Osteoclasts in the Tumor Microenvironment are Associated with Clinical Efficacy of Anti-PD-L1 and Anti-CD38 Combination Treatment in Relapsed or Refractory Multiple Myeloma

First-in-Human Assessment of Feasibility and Safety of Multiplexed Genetic Engineering of Autologous T Cells Expressing NY-ESO -1 TCR and CRISPR/Cas9 Gene Edited to Eliminate Endogenous TCR and PD-1 (NYCE T cells) in Advanced Multiple Myeloma (MM) and Sarcoma

Reduced Relapse Risk in Children with Acute Myeloid Leukemia (AML) Who Experience Septic Shock (SS)

Real-World Treatment Patterns and Transfusion Burden Among US Patients with Newly Diagnosed Myelodysplastic Syndromes (MDS)

Rituximab for Preventing Delayed Hemolytic Transfusion Reaction (DHTR) in Sickle CELL Adult Patients: Outcome of Transfusion and SIDE Effects in 58 CASES

Serum Free Light Chain Assay As an Additional Tool for Defining Response and Progressive Disease in Immunoglobulin Secretory Multiple Myeloma

The Transcriptome of Immunomodulator-Resistant Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only